Drugs / Estradiol/norethindrone acetate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03751124 | Oct 2018 → Feb 2021 | uterine corpus leiomyoma | Myovant Sciences GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Estradiol/norethindrone acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03751124 ↗ |
| Route | Oral | “administered orally once daily” NCT03751124 ↗ |